Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals

Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab

First-in-human trial in US for Gan & Lee type 2 diabetes drug

The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers

Gan & Lee gets U.S. FDA clearance for novel glucagon-like peptide-1 analogue

The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects